Table 1.
Demographic, cognitive, and clinical metrics.
| PDN | PD-MCI | PDD | Linear model | |
|---|---|---|---|---|
| n | 23 | 76 | 16 | – |
| Female, No. [%] | 8 (35) | 18 (24) | 3 (19) | – |
| Age, years | 70 (6) | 72 (6) | 77 (6) | PDD > PDN & PD-MCI |
| Education, years | 12 (2) | 13 (3) | 12 (2) | ~ |
| PD symptom duration, years | 7.4 (5) | 7.3 (4) | 8.5 (5) | ~ |
| MoCA | 26 (2) | 23 (3) | 16 (5) | PDN > PD-MCI > PDD |
| Cognitive Z score | 0.28 (0.48) | −0.81 (0.53) | −1.89(0.57)a | PDN > PD-MCI > PDD |
| Memory domain score | 0.52 (0.86) | −0.82 (0.85) | −1.82(0.67)a | PDN > PD-MCI > PDD |
| Dose, MBq | 294 (20) | 300 (16) | 290 (27) | ~ |
| Aβ positive, No. [%]b | 4 [17] | 11 [14] | 6 [38] | – |
| Mean cortical SUVRNS | 1.11 (0.13) | 1.12 (0.18) | 1.28 (0.30) | PDD > PDN & PD-MCI |
| Mean cortical CL | 16 (19) | 18 (27) | 42 (44) | PDD > PDN & PD-MCI |
Values are mean (standard deviation) unless specified;
a
Cognitive z scores and memory domain scores for seven PDD participants were imputed from restricted neuropsychological data due to their inability to complete the full cognitive assessment.
b
Visual assessment of amyloid positive/negative reported. ~, no evidence of a difference; –, no statistical test applicable or was not performed. Pairwise group estimates were considered different if 95% uncertainty intervals did not overlap. MBq, megabecquerel; MoCA, Montreal Cognitive Assessment; Aβ, Amyloid beta; SUVRNS, Standardized uptake value ratio with “non-standard” processing (see Supplementary Material), CL, centiloid.